January, 2023 Quick Question: Tranexamic Acid

Our January 2023 Quick Question asks, What is the target of the anti-hemorrhagic agent tranexamic acid? For this question, the only correct answer is fibrinolysis. Here are the responses from our 57 participants… Factor V: 5 [9%] Factor XIII: 5 [9%] Fibrinolysis: 40 [70%] Prothrombin 4 [7%] Activated protein C 3 [5%] This QQ is […]

Comments (0)

Quick Question Archive

Dec 30 2022

george

Apixaban and Alzheimer Disease

Michele M. Reed participated in my [Geo] Michigan State University’s Biomedical Laboratory Diagnostics graduate course, BLD 835 Hemostasis and Thrombosis. Her attached manuscript provides basic information about apixaban’s indications and efficacy and makes an intriguing reference to apixaban as a potential means for dementia management. Click here for Michele’s manuscript, “Can Apixaban Help Reduce the […]

Comments (0)

Anticoagulant Therapy

Nov 30 2022

george

November, 2022 Quick Question: PT/INR

The stem or our November 2022 Quick question asked, If you use the PT when no warfarin is being measured, how do you report the results? Our 51 participants responded as follows: Report both PT and INR: 34 [66%] Report PT/MRI ratio: 0 Report PT only: 14 [27%] Report INR only: 4 [7%] Answer 2 […]

Comments (3)

Anticoagulant Therapy

Nov 17 2022

george

Ultracentrifuge Plasma?

Received 11-13-22: Hello, We have an ultracentrifuge in our lab that is used in our chemistry department for lipemic samples. In the coagulation department,

Comments (0)

Anticoagulant Therapy

Nov 15 2022

george

The Dilute Thrombin Time Measures DTIs

Here is the abstract of a pre-publication release comparing direct thrombin inhibitor results from the plasma-diluted thrombin time [DTT] to the partial thromboplastin time [PTT]:

Comments (0)

Anticoagulant Therapy

Nov 9 2022

george

November, 2022 Quick Question

Please visit and respond to our November 2022 Quick Question, submitted by Dave McGlasson. The question asks, "If you use the PT when no warfarin is being measured, how do you

Blog

Dr. Karen Moser Coag Conversation: The DOACs Part 2

Our Coag Conversation series sponsored by BioMedica Diagnostics continues with Dr. Karen Moser

Comments (0)

Anticoagulant Therapy

Oct 13 2022

elaine

Northeast Laboratory Conference 10/18–10/19 2022

At the 2022 Northeast Laboratory Conference, October 18 and 19, I [Geo] presented "Antithrombotic Therapy, Whatever Happened to Warfarin?"

Blog

Dr. Karen Moser’s Coag Conversation: The DOACs

George Fritsma and guest speaker Karen Moser, MD, Medical Director of the Hemostasis and Thrombosis Laboratory at ARUP Laboratories and Associate

Comments (0)

Anticoagulant Therapy

Aug 4 2022

george

Sulodexide Improves Long Covid

Here is a breakthrough study from Tunisia indicating the efficacy of sulodexide [Aterina], the oral “fast-moving heparin”-dermatan sulfate formulation, in managing the endothelial dysfunction of and reducing the symptoms associated with Long Covid. Sulodexide is not FDA-approved for Long Covid therapy. Charfeddine S, Ibnhadjamor H, Jdidi J, et al. Sulodexide significantly improves endothelial dysfunction and […]

Comments (0)

Anticoagulant Therapy

Anticoagulant Therapy

January, 2023 Quick Question: Tranexamic Acid

Apixaban and Alzheimer Disease

November, 2022 Quick Question: PT/INR

Ultracentrifuge Plasma?

The Dilute Thrombin Time Measures DTIs

November, 2022 Quick Question

Dr. Karen Moser Coag Conversation: The DOACs Part 2

Northeast Laboratory Conference 10/18–10/19 2022

Dr. Karen Moser’s Coag Conversation: The DOACs

Sulodexide Improves Long Covid

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question